Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Buy Back as Much as $10M of Its Stock Over Four Years

NEW YORK (GenomeWeb News) — PerkinElmer on Monday said it plans to buy back as much as 10 million shares of its common stock over the next four years.

PerkinElmer’s board authorized the buyback, which will be made over the open market or “through privately negotiated transactions,” the company said.

Two weeks ago, PerkinElmer reported that third-quarter revenues rose 7 percent as profirs slid 7 percent.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.